Patient‐reported outcomes
hypoparathyroidism
HYPOPARATHYROID, SECONDARY, HYPOPARATHYROIDISM
Both HPES and SF‐36 scores improved through week 26 in the TransCon PTH group. The disease‐specific HPES showed improvements in hypoparathyroidism‐related symptoms, functioning, and well‐being for participants treated with TransCon PTH. Treatment with TransCon PTH demonstrated a statistically significant improvement compared with placebo in all key secondary endpoints at week 26: HPES‐Symptom physical (Week 26 Improvement From Baseline in Hypoparathyroid Patient Experience Scale (HPES) Impact and Symptom ScoresAbbreviations: HPES, hypoparathyroid patient experience scale; PTH, parathyroid hormone; SD, standard deviation.Lower scores reflect improvement in hypoparathyroidism‐related symptoms, functioning, and well‐being.Treatment effect of TransCon PTH on the hypoparathyroidism patient experience scale (HPES).Treatment effect of TransCon PTH on general health, 36‐Item Short Form Survey (SF‐36). 